Stock Price of Exact Sciences Corporation (EXAS) Increases 4.41%

Stock price performance of Exact Sciences Corporation is analyzed for various periods using several stock trading signals. In this case, The stock price has rallied 8.37% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -7.26% . Looking at the past 52 week period, the stock price is up at 205.1% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Exact Sciences Corporation has a positive value of 98.22 compared to overall market. For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a 20-day Moving Average of 9.39% and the 50-Day Moving Average is 18.7%.The 200 Day SMA reached 28.1%

Exact Sciences Corporation is having a Relative Strength Index of 66.86 which indicates the stock is not yet over sold or over bought based on the technical indicators. Exact Sciences Corporation (NASDAQ:EXAS) has climbed 4.41% in the past week and advanced 26.89% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 4.29% and the outperformance has advanced to 25.76% for the last 4 weeks period.

Company has reported several Insider transactions to the SEC, on Jan 5, 2017, D Scott Coward (SVP and General Counsel) sold 1,535 shares at 13.61 per share price.On Dec 14, 2016, David Thompson (director) purchased 10,000 shares at 13.84 per share price.On Nov 15, 2016, Graham Peter Lidgard (Chief Science Officer) sold 311,112 shares at 17.52 per share price.

EXACT Sciences Corporation Last issued its quarterly earnings results on Oct 26, 2016. The company reported $-0.36 EPS for the quarter, beating the analyst consensus estimate by $ 0.06. Analyst had a consensus of $-0.42. The company had revenue of $28.12 million for the quarter, compared to analysts expectations of $25.20 million. The companys revenue was up 122.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.45 EPS.

Exact Sciences Corporation (NASDAQ:EXAS) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.05 points or 0.26% at $19.16 with 1,571,564 shares getting traded. Post opening the session at $19.26, the shares hit an intraday low of $18.77 and an intraday high of $19.42 and the price was in this range throughout the day. The company has a market cap of $2,077 million and the number of outstanding shares has been calculated to be 108,410,279 shares. The 52-week high of Exact Sciences Corporation (NASDAQ:EXAS) is $22.8 and the 52-week low is $4.67.

EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.


Share this post

Leave a Reply